juvenile rheumatoid arthritis pipeline insight

DelveInsight’s, “Juvenile Rheumatoid Arthritis - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Juvenile Rheumatoid Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Juvenile Rheumatoid Arthritis: Understanding

Juvenile Rheumatoid Arthritis: Overview

Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of autoimmune and autoinflammatory diseases characterized by chronic arthritis in children under the age of 16, persisting for at least six weeks. The terminology has evolved over time—from juvenile rheumatoid arthritis and juvenile chronic arthritis—to the more inclusive term JIA, adopted in 1995. According to the 2001 consensus by the International League of Associations for Rheumatology (ILAR), JIA is classified into seven distinct categories: oligoarthritis, RF-positive polyarthritis, RF-negative polyarthritis, systemic arthritis, psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis. Each subtype presents with unique clinical features, genetic backgrounds, pathophysiological mechanisms, laboratory profiles, and disease trajectories. While chronic joint inflammation is the hallmark of all forms, many subtypes also involve systemic or extraarticular manifestations. More recently, a data-driven classification system is under development and being validated by the Pediatric Rheumatology International Trials Organization (PRINTO), aiming to better reflect the clinical and biological diversity of JIA.

 

Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease affecting children in the Western world, with incidence rates ranging from 1.6 to 23 per 100,000 children and prevalence varying between 3.8 and 400 per 100,000, depending on study design, disease classification, and geographical location. In North America, studies report an incidence of 0.041 to 0.061 per 1,000 children, while the Utah Population Database estimates a prevalence of 1.2 per 1,000 among white populations. The familial aggregation of JIA is notable, with a relative risk for siblings ranging from 15 to 30—comparable to that observed in type 1 diabetes. Among the subtypes, oligoarthritis is the most frequent (50–60%), followed by RF-negative polyarthritis (11–28%), systemic arthritis (10–20%), RF-positive polyarthritis (2–7%), psoriatic arthritis (2–15%), and enthesitis-related arthritis (1–7%). Uveitis is most frequently observed in northern and southern Europe but is less common in Latin America, Africa, the Middle East, and Southeast Asia. While most JIA subtypes predominantly affect females, enthesitis-related arthritis is more common in males, and systemic JIA affects both sexes equally.

 

The immunopathogenesis of Juvenile Idiopathic Arthritis (JIA) varies across its subtypes but generally involves an imbalance in adaptive immune responses, particularly among regulatory T cells, Th1 cells (interferon-gamma secreting), and Th17 cells (interleukin-17 secreting). In subtypes such as oligoarthritis, polyarthritis, and psoriatic arthritis, IL-17 plays a central role by promoting the release of proinflammatory cytokines and matrix metalloproteinases, ultimately leading to joint damage. In the early stages of rheumatoid arthritis-like subtypes, IL-23 acts as a key cytokine, driving inflammation through IL-17 and tumor necrosis factor (TNF), and contributing to new bone formation via IL-22. In contrast, systemic JIA is characterized by dysregulation of the innate immune system, with persistent activation of monocytes, macrophages, and neutrophils. This innate immune response is driven by proinflammatory cytokines such as IL-1β, IL-6, and IL-18, which are responsible for the systemic features and clinical manifestations distinctive to systemic arthritis.

 

The treatment and management of Juvenile Idiopathic Arthritis (JIA) involve a multidisciplinary approach combining pharmacologic therapy, physical rehabilitation, and supportive care. Anti-inflammatory and immunomodulatory medications form the cornerstone of treatment, with the choice tailored to disease subtype, severity, associated conditions, and family preferences. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for initial symptom relief across all subtypes, though their use has declined with the advent of more aggressive treatment strategies, including disease-modifying antirheumatic drugs (DMARDs) like methotrexate and targeted biologic agents. Physical therapy plays a vital role in maintaining joint mobility and function, with activities such as swimming recommended for providing exercise with minimal joint stress. Moderate fitness, flexibility, and strengthening exercises are encouraged to support overall musculoskeletal health. In some cases, surgical intervention, nutritional support, and psychosocial care may also be necessary to address the broader impacts of the disease.

 

"Juvenile Rheumatoid Arthritis- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Juvenile Rheumatoid Arthritis pipeline landscape is provided which includes the disease overview and Juvenile Rheumatoid Arthritis treatment guidelines. The assessment part of the report embraces, in depth Juvenile Rheumatoid Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Juvenile Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Juvenile Rheumatoid Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Juvenile Rheumatoid Arthritis.

 

Juvenile Rheumatoid Arthritis Emerging Drugs Chapters

This segment of the Juvenile Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Juvenile Rheumatoid Arthritis Emerging Drugs

• Deucravacitinib: Bristol-Myers Squibb

Deucravacitinib is a selective, allosteric inhibitor of tyrosine kinase 2 (TYK2). TYK2 is a member of the Janus kinase (JAK) family. Deucravacitinib binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream activation of Signal Transducers and Activators of Transcription (STATs) as shown in cell-based assays. Janus kinases function as pairs of homo- or heterodimers in the JAK-STAT pathways. TYK2 pairs with JAK1 to mediate multiple cytokine pathways and also pairs with JAK2 to transmit signals as shown in cell-based assays. Currently, the drug is in Phase III stage of its development for the treatment of Juvenile Rheumatoid Arthritis.

 

• Allogeneic  adipose-derived mesenchymal stem cells: Hope Biosciences

Hope Biosciences utilizes allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) as a promising therapeutic approach for juvenile rheumatoid arthritis, also known as juvenile idiopathic arthritis (JIA). These stem cells, sourced from donor adipose tissue, are cultured to maintain purity and consistency, offering immunomodulatory and regenerative properties that may alleviate inflammation and improve joint function. With their ability to target autoimmune responses and promote tissue repair, HB-adMSCs represent an innovative solution for managing the debilitating symptoms of JIA. Currently, the drug is in Phase II stage of its development for the treatment of Juvenile Rheumatoid Arthritis.

 

• MP 1032: MetrioPharm AG

MP1032 is a unique small molecule targeting overshooting reactions of activated immune cells by addressing a central, natural metabolic process occurring in activated immune cells. The mitochondria of these cells react to the activation by boosting their energy metabolism, which in turn leads to the generation of reactive oxygen species (ROS) and an increase of intercellular pH. MP1032 is activated only by clusters of elevated pH and acts as an ROS scavenger, normalizing the pathologically increased ROS levels (oxidative stress). Once the pH returns to normal, the drug stops is no longer activated and working. This unique, self-regulating mechanism of action makes MP1032 a first-in-class anti-inflammatory drug that reduces excessive ROS without interfering with the physiological ROS levels of other cells that are essential for normal cell function, resulting in an excellent safety profile. Currently, the drug is in Phase I stage of its development for the treatment of Juvenile Rheumatoid Arthritis.

Further product details are provided in the report……..

 

Juvenile Rheumatoid Arthritis: Therapeutic Assessment

This segment of the report provides insights about the different Juvenile Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Juvenile Rheumatoid Arthritis

There are approx. 8+ key companies which are developing the therapies for Juvenile Rheumatoid Arthritis. The companies which have their Juvenile Rheumatoid Arthritis drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.

 

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Juvenile Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Juvenile Rheumatoid Arthritis: Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Juvenile Rheumatoid Arthritis therapeutic drugs key players involved in developing key drugs. 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Juvenile Rheumatoid Arthritis drugs.

 

Juvenile Rheumatoid Arthritis Report Insights

• Juvenile Rheumatoid Arthritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Juvenile Rheumatoid Arthritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Juvenile Rheumatoid Arthritis drugs?
• How many Juvenile Rheumatoid Arthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Juvenile Rheumatoid Arthritis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Juvenile Rheumatoid Arthritis therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Juvenile Rheumatoid Arthritis and their status?
• What are the key designations that have been granted to the emerging drugs?